Atara Biotherapeutics (ATRA) EBT Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly EBT Margin came in at 803.29% in Q1 2026, down 84202.0% YoY from N/an in Q1 2025, and down 278.17% on a QoQ basis from 212.41% in Q4 2025.
Atara Biotherapeutics (ATRA) EBT Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 6 years of EBT Margin data on file, last reported at 803.29% in Q1 2026.
- Quarterly EBT Margin fell 84202.0% year-over-year to 803.29% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.7% (down 3285.0% YoY) and the FY2025 annual result came in at 27.11%, up 9335.0% from the prior year.
- EBT Margin fell to 803.29% in Q1 2026, from 212.41% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 2007.94% in Q4 2023 to a low of 43357.93% in Q2 2023.
- A 5-year average of 3792.55% and a median of 119.89% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin tumbled 4339373 bps — and 2024, when it surged 4329141 bps.
- Tracing ATRA's EBT Margin over 5 years: stood at 4205.87% in 2022, then surged by 148 bps to 2007.94% in 2023, then slumped by 102 bps to 38.81% in 2024, then tumbled by 447 bps to 212.41% in 2025, then tumbled by 278 bps to 803.29% in 2026.
- The last three EBT Margin figures came in at 803.29% (Q1 2026), 212.41% (Q4 2025), and 123.81% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 12.09% |
| 10 | Atara Biotherapeutics | 146.12 Mn | 129.57 Mn | 439,000.00 | -767.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -767.14% |
| Mar 31, 2026 | -803.29% |
| Dec 31, 2025 | -212.41% |
| Sep 30, 2025 | -123.81% |
| Jun 30, 2025 | 13.60% |
| Mar 31, 2025 | 38.73% |
| Dec 31, 2024 | -38.81% |
| Sep 30, 2024 | -54.56% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -115.98% |
| Dec 31, 2023 | 2,007.94% |
| Sep 30, 2023 | -3,456.24% |
| Jun 30, 2023 | -43,357.93% |
| Mar 31, 2023 | -8,455.77% |
| Dec 31, 2022 | -4,205.87% |
| Sep 30, 2022 | -1,885.65% |
| Jun 30, 2022 | 35.80% |
| Dec 31, 2021 | -1,239.07% |
| Sep 30, 2021 | -1,576.61% |
| Jun 30, 2021 | -2,164.78% |